BioCryst Pharmaceuticals (BCRX)
(Delayed Data from NSDQ)
$4.45 USD
-0.03 (-0.67%)
Updated May 3, 2024 04:00 PM ET
After-Market: $4.43 -0.02 (-0.45%) 5:28 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$4.45 USD
-0.03 (-0.67%)
Updated May 3, 2024 04:00 PM ET
After-Market: $4.43 -0.02 (-0.45%) 5:28 PM ET
3-Hold of 5 3
D Value A Growth F Momentum C VGM
Zacks News
BioCryst Pharmaceuticals (BCRX) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
BioCryst Pharmaceuticals (BCRX) closed at $3.55 in the latest trading session, marking a -0.28% move from the prior day.
Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Is (BCRX) Outperforming Other Medical Stocks This Year?
RedHill's Oncology Candidate to be Tested for Coronavirus
by Zacks Equity Research
RedHill (RDHL) inks a deal with NIAID for non-clinical testing of its investigational candidate RHB-107 to evaluate its activity against COVID-19. Stock up.
Top Ranked Momentum Stocks to Buy for April 20th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 20th
Are Options Traders Betting on a Big Move in BioCryst Pharmaceuticals (BCRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioCryst Pharmaceuticals (BCRX) stock based on the movements in the options market lately.
BioCryst Begins Study on Galidesivir for Coronavirus Infection
by Zacks Equity Research
BioCryst (BCRX) starts recruitment for a clinical study on its pipeline candidate galidesivir to treat patients with the deadly coronavirus disease.
BioCryst Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
BioCryst Pharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AcelRx, BioCryst, Build-A-Bear, CACI and Evercore
After a Brutal Q1, Q2 Gives a Ray of Hope: 5 Must Buys
by Tirthankar Chakraborty
After the Dow sees a quarter as ugly as this year's first quarter, the 124-year old index on average returns 11.8% in the following quarter. There is similar positive trend for the S&P 500 as well.
Amneal (AMRX) Catches Eye: Stock Jumps 6.7%
by Zacks Equity Research
Amneal (AMRX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Catalyst's (CPRX) Q4 Earnings Miss Estimates, Revenues Meet
by Zacks Equity Research
Catalyst's (CPRX) earnings lag estimates in the fourth quarter. Revenues match the same.
7 Great Stocks for a Small Budget
by Sejuti Banerjea
Take advantage of panic selling with these 7 cheap stocks.
BioCryst (BCRX) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
BioCryst (BCRX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Implied Volatility Surging for BioCryst (BCRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for March 9th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, March 9th
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of 92.00% and 230.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioCryst Pharmaceuticals (BCRX) in Focus: Stock Moves 8.5% Higher
by Zacks Equity Research
BioCryst Pharmaceuticals (BCRX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Will BioCryst Pharmaceuticals (BCRX) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is the Options Market Predicting a Spike in BioCryst (BCRX) Stock?
by Zacks Equity Research
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
BioCryst Submits NDA for Hereditary Angioedema Candidate
by Zacks Equity Research
BioCryst (BCRX) files a new drug application to the FDA for once-daily berotralstat (BCX7353), which is being developed for the prevention of hereditary angioedema attacks.
Implied Volatility Surging for BioCryst (BCRX) Stock Options
by Zacks Equity Research
Investors need to pay close attention to BioCryst (BCRX) stock based on the movements in the options market lately.
BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -60.92%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
BioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
BioCryst (BCRX) delivered earnings and revenue surprises of -9.68% and -42.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?